Why the study?
Does benazepril alter the plasma atrial natriuretic factor (ANF) response to volume expansion in patients with essential hypertension?
Does benazepril alter the plasma atrial natriuretic factor (ANF) response to volume expansion in patients with essential hypertension?
Benazepril blunts and delays the atrial natriuretic factor response to volume expansion in hypertensive patients, likely reflecting improved cardiac performance or compliance due to blood pressure reduction.
Answers are grounded in this paper and cite their sources.
Supports benazepril improving cardiac compliance in hypertension; extends ACEI effects on ANF dynamics to volume challenge.
To verify the hypothesis that the angiotensin converting enzyme (ACE) level may affect the metabolism of circulating atrial natriuretic factor (ANF), the acute and chronic effects of benazepril on plasma ANF levels were studied in hypertensive patients under basal conditions and in response to acute volume expansion. Ten essential hypertensives entered a double-blind crossover study, and were randomly allocated either to placebo or to 10 mg benazepril orally once a day for 2 days; after a placebo washout period of 2 days the groups were crossed over. On the second day of each crossover period, volume expansion was induced by infusing 1 litre saline in 30 min, and blood samples for ANF measurements were drawn at times −5, 0, 5, 15, 30, 35, 40, 50 and 60min. Oral benazepril at 10mg/day was then given to all patients for 4 weeks, and the volume expansion with saline was repeated. After the 2-day acute benazepril treatment, blood pressure fell from 166.1 ± 3.6/105.1 ± 0.9 to 140.1 ± 4.6/85.6 ± 2.1 mmHg (P < 0.01 for both systolic and diastolic blood pressure), whereas ANF fell from 29.4 ± 3.6 to 24.1 ± 3.7 pg/ml (NS) after the acute benazepril treatment and to 17.7 ± 3.6 pg/ml (P < 0.01) after the chronic benazepril treatment. The volume expansion itself did not induce significant changes in mean arterial pressure, either during the placebo treatment or during the acute chronic benazepril treatment. The rise in ANF values in response to saline infusion during placebo was prompt, beginning at min 15 and reaching a maximum at min 40. Following a single dose of benazepril, the saline infusion induced a delayed increase in ANF values which reached statistical significance 35 min after the start of the infusion. Finally, when the volume expansion was repeated after 4 weeks of benazepril treatment, a further delay in the ANF response was seen (no significant changes until mins 50 and 60). These data, while ruling out the hypothesis that ACE affects the metabolism of circulating ANF, might reflect an improvement in cardiac performance or compliance, or both, due to the blood pressure reduction induced by benazepril.
No takes yet. Share an insight, caveat, or question.
Dessı̀-Fulgheri et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: